|Audit||Nominating and Governance||Compensation|
|Jack Goldstein, Ph.D|
Jack Goldstein, PhD, has served as Chairman of the Board of Directors of the Company since March 2010. Dr. Goldstein was president and Chief Operating Officer of Chiron Corporation until its acquisition by Novartis in April 2006. Before Chiron, he spent two years as a general partner at Windamere Venture Partners. Dr. Goldstein was president and Chief Executive Officer of Applied Imaging Corporation from 1997 to 2001 as well as Chairman of the Board of Directors from 2000 to 2002. He continued as a Director on that board until 2006. Prior to Applied Imaging, Dr. Goldstein spent 11 years at Ortho Diagnostic Systems, a Johnson & Johnson company, in various executive positions, including four years as president. He was earlier vice president of research and development at a division of Baxter Healthcare Corporation. Dr. Goldstein earned a Bachelor of Arts degree in biology from Rider University and a Master of Science degree in immunology and doctorate in microbiology from St. John's University. He currently sits on the board of directors of Accuray, Inc. and previously served on the boards of Immucor, Inc., OraSure Technologies, Inc. and Illumina, Inc.
President & Chief Executive Officer
Mr. Scott Cormack has more than two decades of experience in the biotechnology industry in executive management and venture capital. Scott has been President and CEO since August 2008, when OncoGenex Technologies Inc. completed a reverse takeover of Sonus Pharmaceuticals, Inc. to become OncoGenex Pharmaceuticals, Inc. Scott has led OncoGenex through significant corporate milestones, including private financings, leading the company from pre-clinical studies to completion of multiple Phase 2 clinical trials, initiation of Phase 3 trials and development of a robust pipeline. Scott was a co-founder of OncoGenex Technologies Inc., now a wholly owned subsidiary, where he served as President and a member of the Board of Directors since May 2000 and as Chief Executive Officer since February 2002. From 1998 to 2001, Scott served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities and joint venture between RBC Technology Ventures Inc. and Research Corporation Technologies. While at Milestone Medica, Scott served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1995 to 1998, Scott served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company. He was President and founder of For Tomorrow, a sole proprietorship engaged in business consulting, from 1991 to 1999. From 1986 to 1988, Scott served as Territory Manager of Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products for human and animal health markets, and from 1988 to 1991 he served as its Technology Manager, Immunomodulators. Scott holds a B.S. degree from the University of Alberta.
|Neil James Clendeninn, Ph.D, MD|
Dr. Clendeninn is currently a practicing physician and serves as Program Director for Palliative Medicine Partners: Complex Illness Coordination, a program of Kauai Hospice in Kauai, Hawaii. Dr. Clendeninn has more than 25 years of pharmaceutical industry and clinical experience. He also recently served as Senior Vice-President and Chief Medical Officer of Heron Therapeutics from 2015 to 2016. He is also active in clinical development consulting for the biopharmaceutical industry. Previously, Dr. Clendenin served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Affairs Department from pre-clinical to phase IV. He and his team were responsible for the rapid development and delivery to market of Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, PhDs, clinical pharmacologists, biostatisticans, data management and a post-marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, Board of Scientific Advisors of the National Cancer Institute and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. He has written and co-authored numerous publications and has been an editor of several textbooks. Dr. Clendeninn currently serves on the Boards of OncoGenex Technologies Inc. and OncoGenex Pharmaceuticals. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a PhD Microbiology/Pharmacology and MD from New York University, NY. He completed an Internal Medicine residency at University of Washington, and an Oncology fellowship and post-doc at NCI, NIH in Bethesda, MD.
|Martin Mattingly, PharmD|
Dr. Mattingly has served as a director of the Company since June 2010. Since August 2012, Dr. Mattingly has served as a member of Tech Coast Angels. Previously, Dr. Mattingly served as the Chief Executive Officer of Trimeris, Inc., a biopharmaceutical company, from November 2007 until its merger with Synageva in November 2011. He also served on the Board of Directors of Trimeris, Inc. from November 2007 until November 2011. From 2005 to 2007, Dr. Mattingly was employed at Ambrx, Inc., a biopharmaceutical company, where he served as President and Chief Executive Officer. From 2003 to 2005, Dr. Mattingly served as Executive Vice President and Chief Operating Officer of CancerVax Corporation, a biotechnology company. From 1996 to 2003, he provided senior leadership in various management positions at Agouron Pharmaceuticals, Inc. and Pfizer, Inc., including serving as General Manager of the Agouron HIV division, Vice President, Product Development Group at Pfizer and Vice President, Global Marketing Planning at Pfizer. Dr. Mattingly holds a Doctor of Pharmacy degree from the University of Kentucky.
Stewart Parker has served as a director of the Company since March 2010. She served as the CEO of The Infectious Disease Research Institute (IDRI), a not for profit global health research institute from March 2011 to January 2014. Ms. Parker managed the formation of Targeted Genetics and served as President, Chief Executive Officer and a director of Targeted Genetics since its spinout from Immunex in 1992 to 2008. She served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. Ms. Parker also served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products, from February 1991 to January 1993. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry, and as a director of several privately held companies. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
David V. Smith, has served as a director of the Company since August 2010. Mr. Smith has more than 30 years of financial and operational management experience, and has held leadership positions in the biotechnology industry for more than two decades. He was recently appointed Chief Operating Officer at IntegenX. Prior to IntegenX, Mr. Smith served as the Executive Vice president and Chief Financial Officer of Thoratec Corporation. Prior to joining Thoratec in 2006, Mr. Smith served as Vice President and Chief Financial Officer of Chiron Corporation. Prior to Chiron, Mr. Smith was the Vice President of Finance and Chief Financial Officer at Anergen Incorporated. He has also served in various financial management positions with Genentech, Inc., both in the United States and Europe, and previously held finance positions at Syntex Corporation and IBM Corporation. Mr. Smith earned a B.A. in Economics and History from Willamette University and an M.B.A. in Finance from Golden Gate University. Previously, he was a member of the board of directors and chair of the audit committee of Perlegen Sciences, Inc.
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2017 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.